메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

MGI Tech and JCBio Announce Collaboration on DCS Lab Project to Advance Multi-Omics Innovation in South Korea

CHANGCHUN, China, Aug. 29, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. ("JCBio"), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with
- 김갑성 기자
- 2025-08-29 17:29
Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI, Aug. 29, 2025 -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market. Leveraging the vital platform for global enterprises to access the Chinese massive market, many exhibitors have grown from participants into investors, while numerous exhibits have been transformed into marketable goods. Novartis, for instance, debute
- 김갑성 기자
- 2025-08-29 16:44
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

[ 메디채널 김갑성 기자 ] 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2] Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the dai
- 김갑성 기자
- 2025-08-29 14:00
Alphamab Oncology Reports 2025 Interim Results and Business Highlights

SUZHOU, China, Aug. 29, 2025 -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business progress. Financial Summary For the six months ended June 30, 2025, we recorded total revenue of RMB 319.44 million, an increase of 84.05% compared with the first half of 2024. Meanwhile, product revenue (attributed to the Company) amounted to RMB 67.02 million. For the six months ended June 30, 2025, our R&D expenditure amounted to RMB 253.16 million, an increase of 30.14% compared with the fir
- 김갑성 기자
- 2025-08-29 09:53
Mayapada Healthcare Holds Commencement Ceremony for an International Hospital in the Batam Tourism and International Healthcare SEZ

JAKARTA, Indonesia, Aug. 29, 2025 -- Mayapada Healthcare (IDX:SRAJ), the healthcare services arm of Mayapada Group, held a commencement ceremony to mark the development of its international-standard hospital, Mayapada Apollo Batam International Hospital (MABIH), located in Batam Tourism and International Healthcare Special Economic Zone (SEZ), Sekupang, Batam, Riau Islands. The ceremony was led by the Chairman of Batam Indonesia Free Trade Zone Authority (BP Batam), Amsakar Achmad. The ceremony marks a significant step in strengthening Indonesia's national healthcare ecosystem while reducing
- 김갑성 기자
- 2025-08-29 09:23
HEC Group and JungKwanJang Form Strategic Alliance to Drive a New Era in Eastern Tonic Health

SINGAPORE, Aug. 29, 2025 -- The JungKwanJang delegation included Kim Yang-jin, Director General of the Overseas Business Division; Jung Jong, Director General of the Asia-Pacific Business Division; and Kim Jong-sik, Director of the Future Business Research Institute, along with five other representatives. HEC Group was represented by Director and General Manager Tang Xinfa; Lu Yuxin, Director and General Coordinator of the Health Industry; Li Wenjia, Deputy General Coordinator of the Health Industry and Dean of the Health Research Institute; Chen Hao, General Manager of HEC Pharmacy C
- 김갑성 기자
- 2025-08-29 08:15
Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 29, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update. "In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our 'dual-engine' strategy," commented Rogers Yongqing Luo, CEO of Everest Medicines. "We have built a co
- 김갑성 기자
- 2025-08-29 07:52
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs

TOKYO, Aug. 28, 2025 -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC's iPSC technology to accelerate robust and scalable expansion of iPSC-HSPCs. In this project, Celaid's human HSC expansion technology will be applied to AGC's iPSC-HSPCs. The functionality of the expanded cells will be evaluated thr
- 김갑성 기자
- 2025-08-28 22:00
Coventry Responds to Lapetus's Secrecy Claim

[ 메디채널 황정호 기자 ] Urges transparency on life expectancy accuracy Following Lapetus's imminent closure, argues elimination of any claim to trade secret protection TALLAHASSEE, Fla., Aug. 28, 2025 -- Coventry First LLC ("Coventry"), the market leader in life settlements, this week filed a legal response opposing Lapetus Solutions, Inc.'s ("Lapetus") attempt to block disclosure of statutorily required life expectancy audit reports. The filing underscores Coventry's long-held view that the integrity of the life settlement market demands transparency around the ac
- 황정호 기자
- 2025-08-28 21:05
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers

Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treated with a KRAS G12C inhibitor Orphan Drug Designation was granted for treatment of colorectal cancer (CRC) harboring KRAS G12C mutant protein. SHANGHAI, Aug. 28, 2025 -- D3 Bio, Inc, a clinical-stage oncology company focuses on discovery and development of precision oncology therapies
- 김갑성 기자
- 2025-08-28 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 30일 17시 20분